Immunotherapy Plus Chemoradiation Improves Overall Survival in ...

Patients who received chemoradiation alone, RT alone or RT plus immunotherapy had worse OS compared to patients who received chemotherapy plus immunotherapy (HR ...

The addition of immunotherapy to chemotherapy, RT, and chemoradiation was associated with improved OS compared with chemotherapy alone, ...

Immunotherapy Plus Chemoradiation Improves Overall Survival in ...

Patients who received immunotherapy had better median OS compared to patients who did not receive immunotherapy (13.2; 95% CI: 12.7–13.9 months vs 8.0; 95% CI: ...

Studies Show Immunotherapy Improves Long-Term Survival in ...

Immunotherapy, which works by enabling the body's immune system to recognise and destroy cancer cells improves long-term overall survival in ...

Studies Show Immunotherapy Improves Long-Term Survival in ...

Results showed a statistically significant and clinically meaningful improvement in overall survival with immunotherapy plus chemotherapy before ...

Pembrolizumab Plus Chemoradiotherapy Significantly Improves OS in

Median OS was not reached in either group; 36-month OS was 82.6% (95% CI 78.4–86.1) in the pembrolizumab-chemoradiotherapy group and 74.8% (95% ...

Immunotherapy at any line of treatment improves survival in patients ...

Immunotherapy as first‐line was given to 39 patients (13.7%), second‐line to 140 (48.8%), and as third‐line and beyond to 108 (37.6%). Median overall survival ...

Pembro Plus Platinum-Based Chemotherapy Improves Survival in ...

The duration of best overall response was 5.8 and 5.5 months for the chemotherapy and pembrolizumab arm and chemotherapy-alone arm. Response- ...

Eftilagimod Alpha Plus Pembrolizumab/Chemo Generates Improved ...

Eftilagimod alpha combined with pembrolizumab and chemotherapy improved overall and progression-free survival in metastatic nonsquamous NSCLC ...

Pembrolizumab or placebo with chemoradiotherapy followed by ...

Pembrolizumab plus chemoradiotherapy significantly improved overall survival in patients with locally advanced cervical cancer These data ...

KEYTRUDA® (pembrolizumab) Plus Trastuzumab and ... - Merck.com

KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy ...

Dual immunotherapy plus chemotherapy benefits specific subset of ...

In these patients, adding tremelimumab to durvalumab and chemotherapy resulted in higher overall response rates (42.9%) relative to patients who ...

Chemotherapy plus immunotherapy improves survival in patients ...

Both overall survival and progression-free survival were higher in patients on the immunotherapy-chemotherapy regimen after almost three years.

Overall survival according to immunotherapy and radiation treatment ...

Within the NCDB, patients with stage IV NSCLC receiving immunotherapy experienced improved OS compared to patients receiving chemotherapy. These ...

Immunotherapy Improves Survival in Advanced Esophageal Cancer

In people with advanced esophageal cancer, combining nivolumab (Opdivo) with either chemotherapy or ipilimumab (Yervoy) improved how long ...

Pembrolizumab Plus Chemo Improves Overall Survival in ...

Perioperative pembrolizumab plus chemotherapy improves overall survival in patients with resectable gastric cancer.

Combining radiation plus immunotherapy to improve systemic ...

Together, radiation and immunotherapy offer potential to eliminate metastatic disease, reduce time to recurrence and improve overall survival. Major obstacles ...

Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With ...

Pembrolizumab plus chemotherapy improved overall survival (hazard ratio, 0.64; 95% confidence interval [CI]: 0.51‒0.79) and progression-free survival ...

Immunotherapy Among Patients With Brain Metastases Whose ...

Results varied with other combined therapies; immunotherapy plus radiation therapy was associated with improved overall survival compared with ...

Improved survival for patients with lung cancer treated ... - The Lancet

The median estimated 3-year overall survival was 71% (95% CI 66–76) in the perioperative pembrolizumab group compared with 64% (58–69) in the ...